Crossmark

The need for ethical guidance for the use of patient-reported outcomes in research and clinical practice

Published Online: 2021-03-04

Published Print: 2021-04

Authors

Cruz Rivera, Samantha

Mercieca-Bebber, Rebecca

Aiyegbusi, Olalekan Lee https://orcid.org/0000-0001-9122-8251
Scott, Jane

Hunn, Amanda

Fernandez, Conrad https://orcid.org/0000-0002-0746-8306
Ives, Jonathan

Ells, Carolyn

Price, Gary

Draper, Heather

Calvert, Melanie J. https://orcid.org/0000-0002-1856-837X
Funding

Funding for this research was provided by:

DH | National Institute for Health Research

NIHR Biomedical Research Centre Demand Hub
License Information

Text and Data Mining valid from 2021-03-04

Version of Record valid from 2021-03-04
More Information

Article History

First Online: 4 March 2021

Competing interests

: M.J.C. receives funding from Macmillan Cancer Support and UCB Pharma, and has received personal fees from Astellas, Takeda, Merck, Daiichi Sankyo, Glaukos, GlaxoSmithKline and the Patient-Centered Outcomes Research Institute outside the submitted work. O.L.A. declares personal fees from Gilead Sciences and GlaxoSmithKline outside the submitted work. J.S. is an employee of Janssen-Cilag UK and holds stock in Johnson & Johnson.

Document is current